Catalyst
Slingshot members are tracking this event:
FDA Grants Rare Pediatric Disease Designation to Sangamo's (SGMO) SB-318 for Mucopolysaccharidosis Type I (MPS I)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SGMO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Rare Pediatric Disease Designation, Sb-318, Mucopolysaccharidosis Type I, Mps I
